EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL

被引：0

作者：

Gettinger, Scott ^{[1
]}

Horn, Leora ^{[2
]}

Antonia, Scott J. ^{[3
]}

Spigel, David R. ^{[4
]}

Gandhi, Leena ^{[5
]}

Sequist, Lecia V. ^{[6
]}

Sankar, Vindira ^{[7
]}

Ahlers, Christoph M. ^{[7
]}

Wigginton, Jon M. ^{[7
]}

Kollia, Georgia ^{[7
]}

Gupta, Ashok ^{[7
]}

Brahmer, Julie R. ^{[8
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Bristol Myers Squibb Co, New York, NY 10154 USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

programmed death-1 receptor; nivolumab; NSCLC; subpopulations;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.11-038

引用

页码：S909 / S909

页数：1

共 50 条

[41] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
Sosman, Jeffrey Alan
Martin-Algarra, Salvador
Wolchok, Jedd D.
Sharfman, William Howard
Bhatia, Shailender
Hodi, F. Stephen
Hwu, Wen-Jen
Gajewski, Thomas
Slingluff, Craig L.
Kaufman, Howard
Gupta, Manish
McGirr, Analia
Horak, Christine E.
Ahlers, Christoph Matthias
Wigginton, Jon M.
Urba, Walter John
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Sznol, Mario
Kluger, Harriet M.
Hodi, F. Stephen
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne Louise
Atkins, Michael B.
Powderly, John D.
Sharfman, William Howard
Puzanov, Igor
Smith, David C.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Sosman, Jeffrey Alan
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[43] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Gettinger, S.
Horn, L.
Antonia, S. J.
Spigel, D.
Gandhi, L.
Sequist, L. V.
Wigginton, J. M.
Kollia, G.
Gupta, A.
Brahmer, J. R.
ANNALS OF ONCOLOGY, 2012, 23 : 405 - 406
[44] A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC).
Gettinger, Scott N.
Brahmer, Julie R.
Rizvi, Naiyer A.
Ready, Neal
Chow, Laura Quan Man
Antonia, Scott J.
Buyse, Marc E.
Jassem, Jacek
Finckenstein, Friedrich Graf
Crino, Lucio
Lynch, Thomas James
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[45] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
Sznol, M.
Powderly, J. D.
Smith, D. C.
Brahmer, J. R.
Drake, C. G.
McDermott, D. F.
Lawrence, D. P.
Wolchok, J. D.
Topalian, S. L.
Lowy, I.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46] Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis
Hara, Hiroki
Kojima, Takashi
Hironaka, Shuichi
Kato, Ken
Tsushima, Takahiro
Ura, Takashi
Doki, Yuichiro
Ohtsu, Atsushi
Hamamoto, Yasuo
Kitagawa, Yuko
ANNALS OF ONCOLOGY, 2016, 27
[47] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
Kluger, H.
Sznol, M.
Callahan, M.
Postow, M.
Gordon, R.
Segal, N. H.
Rizvi, N.
Lesokhin, A.
Atkins, M. B.
Kirkwood, J.
Burke, M.
Ralabate, A.
Rivera, A.
Kronenberg, S.
Agunwamba, B. U.
Feely, W.
Hong, Q.
Krishnan, S.
Wolchok, J.
ANNALS OF ONCOLOGY, 2014, 25
[48] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amin, Asirn
Ernstoff, Marc S.
Infante, Jeffrey R.
Heng, Daniel Yick Chin
Rini, Brian I.
Plimack, Elizabeth R.
McDermott, David F.
Kollmannsberger, Christian K.
Reaume, Martin Neil
Spratlin, Jennifer L.
Knox, Jennifer J.
Voss, Martin Henner
Pal, Sumanta Kumar
Shen, Yuri
Dhar, Arindarn
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[49] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
Sangro, Bruno
Crocenzi, Todd S.
Welling, Theodore Hobart
Inarrairaegui, Mercedes
Prieto, Jesus
Fuertes, Carmen
Delanty, Laurie
Feely, William
Anderson, Jeffrey
Grasela, Dennis M.
Wigginton, Jon M.
Gupta, Ashok Kumar
Melero, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
Hodi, Stephen
Sznol, Mario
Kluger, Harriet M.
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne L.
Atkins, Michael B.
Powderly, John D.
Sharfman, William H.
Puzanov, Igor
Smith, David C.
Leming, Philip D.
Lipson, Evan J.
Taube, Janis M.
Anders, Robert A.
Horak, Christine E.
Kollia, Georgia
Gupta, Ashok
Sosman, Jeffrey A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177

← 1 2 3 4 5 →